Boehringer Ingelheim Presents First Results of Phase II Study of … – RedOrbit

Boehringer Ingelheim Presents First Results of Phase II Study of
RedOrbit
Through research, treatments and patient-centric support services, the Boehringer Ingelheim (BI) lung health portfolio is designed to help address the challenges people living with a lung disease face every day. Leveraging the company's It is the
First Phase III Data for Tiotropium in Symptomatic Asthma Patients Treated Sacramento Bee

all 53 news articles »

View full post on world asthma day – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *